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Objective: A recent, global, increase in the use of opioids including the prescribing,
highly potent, fentanyl has been recorded. Due its current popularity and the potential
lethal consequences of its intake, we aimed here at analyzing the fentanyl misuse,
abuse, dependence and withdrawal-related adverse drug reactions (ADRs) identified
within the European Medicines Agency (EMA), the United Kingdom Yellow Card Scheme
(YCS), and the United States Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) databases.
Methods: Descriptive analysis of both ADRs and related cases.
Results: The analysis of fentanyl-related misuse, abuse, dependence and withdrawal
cases reported during years 2004–2018 to the EMA, the YCS, and the FAERS
showed increasing levels overtime, specifically, EMA-related data presented two peaks
(e.g., in 2008 and 2015), whilst the FAERS dataset was characterized by a dramatic
increase of the ADRs collected over the last 18 months, and particularly from
2016. Some 127,313 ADRs (referring to n = 6,161 patients/single cases) related to
fentanyl’s misuse/abuse/dependence/withdrawal issues were reported to EMA, with
14,287 being judged by the reporter as “suspect.” The most represented ADRs
were: “drug dependence “(76.87%), “intentional product misuse” (13.06%), and “drug
abuse” (7.45%). Most cases involved adult males and the concomitant use of other
prescribing/illicit drugs. A range of idiosyncratic (i.e., ingestion/injection of transdermal
patches’ fentanyl) and very high-dosage intake cases were here identified. Significant
numbers of cases required either a prolonged hospitalization (192/559 = 34.35%) or
resulted in death (185/559 = 33.09%). Within the same time frame, YCS collected some
3,566 misuse/abuse/dependence/withdrawal ADRs, corresponding to 1,165 single
patients/cases, with those most frequently reported being “withdrawal,” “intentional
product misuse,” and “overdose” ADRs. Finally, FAERS identified a total of 19,145
misuse/abuse/dependence/withdrawal-related cases, being “overdose,” withdrawal,
and “drug use disorder/drug abuse/drug diversion” the most represented ADRs
(respectively, 43.11, 20.80, and 20.29%).
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Conclusion: Fentanyl abuse may be considered a public health issue with significant
implications for clinical practice. Spontaneous pharmacovigilance reporting systems
should be considered for mapping new trends of drug abuse.
Keywords: opioids, fentanyl, prescription drug misuse, opioid-related deaths, new psychoactive substances
INTRODUCTION
The Current “Opioid Crisis”
During recent years, a massive, worldwide increase (United
Nations Office on Drugs, and Crime [UNODC], 2018a) in the
prescription of opioids for pain has been recorded (Guevremont
et al., 2018). This has been associated with increasing risks of
diversion, abuse, morbidity and mortality, with a rising number
of deaths and treatment admissions observed. Such “opioid crisis”
(Throckmorton et al., 2018) started in 2013 (National Institute
on Drug Abuse [NIDA], 2017; O’Donnell et al., 2017), and in
recent years has reached the magnitude level of a public health
issue, being tramadol, fentanyl and oxycodone the most involved
molecules (Stannard, 2012; Centers for Disease Control and
Prevention [CDC], 2014; Van Amsterdam and Van den Brink,
2015; Helmerhorst et al., 2017; Jordan et al., 2017; Floyd and
Warren, 2018). In the United States in 2016, nearly 4% of the
population aged 12 years and older reported a non-medical, past-
year, use of prescription opioids. Compared with heroin use,
which has been increasing each year since 2007, the non-medical
use of prescription opioids has shown a stable trend in the past
5 years. Even though the most commonly misused prescription
opioids reported in the National Survey on Drug Use and Health
in the United States are hydrocodone, oxycodone, codeine and
tramadol, fentanyl appeared to be on the rise (World Drug
Report, 2018). According to the European Monitoring Centre
for Drug and Drug Addiction [EMCDDA] (2018a), in addition
to heroin, other opioid products have been seized in European
countries, including tramadol, buprenorphine, methadone, but
also fentanyl derivatives, with figures respectively, being: 3,553,
3,523, 1,245, and 738 seizures, with overtime increasing levels of
availability of the latter. In Europe, fentanyl issues seem to be
particularly relevant in Estonia (European Monitoring Centre for
Drug and Drug Addiction [EMCDDA], 2018a). Considering data
from the United States Unintentional Drug Overdose Reporting
System (SUDORS), fentanyl has been detected in 56.3% of 5,152
opioid-related deaths during the months July–December 2016
(O’Donnell et al., 2017). In 2016, the United States synthetic
opioid-related deaths accounted for 30.5% of all drug overdose
fatalities and 45.9% of all opioid-related deaths, with a 100%
increase in the rate of these fatalities compared with the previous
year (Center for Disease Control and Prevention [CDC], 2018a,b;
Seth et al., 2018; World Drug Report, 2018; News Release, 2018).
Although Europe does not seem to face a problem of the
same scale of the United States (Van Amsterdam and Van den
Brink, 2015), after a downward trend in opiate use since the late
1990s and until 2013, opiate use rates and drug-related deaths
have started increasing again in Western and Central Europe
(United Nations Office on Drugs, and Crime [UNODC], 2018b),
In 2016, the use of opioids (e.g., heroin, but also: methadone,
buprenorphine, fentanyl, codeine, morphine, tramadol and
oxycodone) was reported as the main reason by 37% of all
clients who entered European specialized drug clinics (European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
2018a). The United Kingdom, Spain, and Sweden present
with the most significant levels of non-medical, opioid-based,
prescription drug use (United Nations Office on Drugs, and
Crime [UNODC], 2018b). In France, the national OPPIDUM
(“Observation of illegal drugs and misuse of psychotropic
medications”) program of the French addictovigilance network
(Frauger et al., 2017), anonymously collects information on
drug abuse and dependence observed in patients recruited in
specialized drug care centers. In 2015, OPPIDUM reported high
percentages (77%) of opiate maintenance treatment among a
number of 5,003 drug users, highlighting the emerging misuse
of a range of synthetic opioids, such as tramadol, oxycodone,
and fentanyl. In Germany, during years 2005–2014, a number
of 242 fentanyl-related overdose fatalities were reported, with
the onset of fentanyl-related deaths following the local launch
of transdermal fentanyl matrix patches in 2004 (Sinicina et al.,
2017).
The Emerging Threat of Illicit Fentanyl
Products
In Europe, during 2016–2017 fentanyl has been involved in
more than 250 fatalities (European Monitoring Centre for
Drug and Drug Addiction [EMCDDA], 2018a); this may have
been associated with fentanyl derivatives’ high potency, possible
use by opioid-naive individuals, and recently increased drug
availability levels. In the United Kingdom, in early 2017, fentanyl
and its synthetic analogs, such as carfentanil, butyryl fentanyl,
fluorobutyrylfentanyl, furanylfentanyl, and alfentanil, have been
detected in 25 drug-related fatalities (Hikin et al., 2018).
Different fentanyl derivatives have been developed by
the legitimate pharmaceutical industry by adding various
substituents to the basic molecule in order to modify the potency
(European Monitoring Centre for Drug and Drug Addiction
[EMCDDA], 2015). The same approach has been mimicked
by chemists in clandestine laboratories to produce new, illicit,
fentanyl derivatives. In fact, an overall number of 38 new
synthetic opioids have been detected in the European drug
market since 2009, out of these, 28 pertained to the fentanyls’
category (European Monitoring Centre for Drug and Drug
Addiction [EMCDDA], 2018a). The vast range of illicit fentanyls
(Gladden et al., 2016; National Institute on Drug Abuse [NIDA],
2017; Armenian et al., 2018; Center for Disease Control and
Prevention [CDC], 2018b; Pichini et al., 2018) are manufactured
in a range of non-EU countries (Macmadua et al., 2017; European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
Frontiers in Pharmacology | www.frontiersin.org 2 February 2019 | Volume 10 | Article 46
fphar-10-00046 January 31, 2019 Time: 10:8 # 3
Schifano et al. Fentanyl Misuse ADRs Reported
2018b) and then made available from both the streets and the
web to be typically self-administered either on their own or
in combination with remaining psychoactives. Users are often
unaware of the contents of the substance they are taking, which
inevitably leads to a great number of fatal overdoses (Helander
et al., 2017; Zawilska, 2017; Kuczyñska et al., 2018; World Drug
Report, 2018).
Fentanyl, Clinical Pharmacological
Issues
Fentanyl is an extremely fast-acting synthetic narcotic analgesic,
first approved as an anesthetic in 1963 (Drummer, 2018;
Food and Drug Administration [FDA], 2018). Currently it
is available for intravenous (I.V.) and intramuscular (I.M.)
injection, but also as transdermal patches, quick acting lozenges,
and dissolving tablets and films. Fentanyl has a potency of at
least 80 times that of morphine, and it is indicated for the
treatment/management of chronic, malignant, and post-surgical
pain conditions (Stanley, 2014; Drummer, 2018). Fentanyl is a
narcotic analgesic acting predominately at the µ-opiate receptor
(Drummer, 2018). Apart from the analgesic characteristics,
the fentanyls as a group produce drowsiness, relaxation and
euphoria, the latter being less pronounced than with heroin
and morphine. The most common side effects include nausea,
dizziness, vomiting, fatigue, headache, constipation, anemia,
and peripheral oedema (European Monitoring Centre for Drug
and Drug Addiction [EMCDDA], 2015; Prekupec et al., 2017).
A range of severe toxicity effects, including muscle rigidity,
seizures, overdoses, and death due to respiratory arrest, have been
reported as well (Zawilska, 2017). Tolerance and dependence
develop rapidly after repeated use. Characteristic withdrawal
symptoms (sweating, anxiety, diarrhea, bone pain, abdominal
cramps, shivers or “goose flesh”) occur when use is stopped too
quickly (Zawilska, 2017). Serious interactions can occur when
fentanyls are mixed with heroin, cocaine, alcohol and other
CNS depressants, e.g., benzodiazepines. Sudden fatalities may
be related to a cardiac arrest or severe anaphylactic reactions.
The estimated lethal dose of fentanyl in humans is 2 mg. The
recommended serum concentration for analgesia is 1–2 ng/ml
and for anesthesia it is 10–20 ng/ml. Blood concentrations of
approximately 7 ng/ml or greater have been associated with
fatalities where poly- substance use was involved (European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
2015). Whilst fatalities have been reported after therapeutic
use, many deaths have occurred as a result of the misuse of
pharmaceutical products. Both used and unused fentanyl patches
have been injected, smoked, snorted or taken orally with fatal
consequences (Lilleng et al., 2004; Woodall et al., 2008; European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
2015).
Fentanyl and Derivatives’ Misuse/Abuse
Issues
The diversion of prescription fentanyl may involve individuals
obtaining medication inappropriately through their profession,
patients using their own prescribed fentanyl recreationally
for a non-medically intended purpose, and subjects using a
medication being prescribed to another person. Typical sources
of medications included friends, family members, and online
pharmacies (Novak et al., 2016).
Recreational fentanyl (also known by the street names
“China White,” “Synthetic Heroin,” “Tango and Cash,” etc.,
Zawilska, 2017) consumption seems to be often associated with
the use of other drugs such as heroin, other opiate/opioid
medicines, alcohol, cocaine, benzodiazepines, psychostimulants,
and antidepressants, and may lead to fatal and non-fatal
overdoses (Uusküla et al., 2015; National Institute on Drug
Abuse [NIDA], 2016; Alcohol and Drug Foundation [ADF], 2018;
Armenian et al., 2018; Drummer, 2018; Kuczyñska et al., 2018).
Even under medical surveillance, the risk of overdose when
injecting fentanyl would be significantly higher than when
injecting heroin (Frisoni et al., 2018). Fentanyl overdoses may
start suddenly, with a potentially lethal respiratory depression
possibly being reached within 2 min as opposed to some
20–30 min after heroin use (Abdulrahim et al., 2018); moreover,
the high rate of fentanyl deaths may be explained as well
by the molecule polydrug consumption. Naloxone, often in
repeated doses, followed by a significant amount of post-
emergency clinical observation time (Greene et al., 2018; Santos
et al., 2019) is used to treat fentanyl’s overdoses (Prekupec
et al., 2017; Zawilska, 2017; Armenian et al., 2018; European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
2018a), although at times this proves unsuccessful (Kuczyñska
et al., 2018). A range of harm-reduction strategies have been
implemented both in Europe (European Monitoring Centre
for Drug and Drug Addiction [EMCDDA], 2016) and in the
United States (New York City Health, 2017).
The improper use of transdermal patches, either by applying
multiple patches on the body, or injecting/insuﬄating/inhaling
(after volatilization) the contents of a discarded patch has
been reported (National Institute on Drug Abuse [NIDA],
2017; Sinicina et al., 2017; Drummer, 2018; Jones et al., 2018;
Kuczyñska et al., 2018). The fentanyl’s rewarding effects are
increased when the drug is injected or self-administered with
nasal sprays/e-liquids, which are vaped using electronic cigarettes
(European Monitoring Centre for Drug and Drug Addiction
[EMCDDA], 2018a).
Due to the growing fentanyl toxicity issues and their high
abuse liability/dependence potential, all fentanyls approved
for medical use are internationally controlled as Schedule II
drugs under the Controlled Substance Act (National Institute
on Drug Abuse [NIDA], 2018) and as a Class A drug
under the Misuse of Drugs Act in the United Kingdom
(GOV.UK, 1971). In 2017, also the fentanyl precursors 4-anilino-
N-phenethylpiperidine (ANPP) and N-phenethyl-4-piperidone
(NPP), have been added to Table 1 of the 1988 United
Nation Convention, and in 2018 have been included under
the European drug monitoring regulations (Abdulrahim et al.,
2018; European Commission (EC), 2018). Nonetheless, over the
last few years there have been growing concerns regarding a
range of illicitly manufactured fentanyl analogs being used as
new/novel psychoactive substances (NPS) (European Monitoring
Centre for Drug and Drug Addiction [EMCDDA], 2015, 2018a,b;
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TABLE 1 | Data relating to fentanyl misuse/abuse/dependence/withdrawal-related ADRs reported to the European Medicines Agency (EMA), the Medicines and
Healthcare products Regulatory Agency (MHRA), and the Food and Drug Administration (FDA) pharmacovigilance databases, 2004–2018.
Characteristics EMA EV Data MHRA YCS Data FAERS Data
Fentanyl misuse/abuse/
dependence/withdrawal -related issues
127,313 (e.g., 6,161 Individual cases);
14,287 “suspect” (e.g., 559 CASES)
3,566 Reactions (e.g., 1,165 Individual
cases)
19,145 Individual cases
Most frequently reported ADRS’ issues Drug dependence (76.9%), Intentional
product misuse (13.1%), Drug abuse
(7.5%)
Withdrawal (24.9%), Intentional product
misuse and use issues (19.6%),
Overdose (17.6%)
Overdose (42.1%), Withdrawal
(20.5%), Drug abuse (20.0%)
Age (years) Adult Adult N/A
Age group 35–64 (229/559 = 41%) Age group:
50–59 (164/1,165 = 14.1 %)
40–49 (144/1,165 = 12.4%)
60–69 (141/1,165 = 12.1 %)
Gender Male (M/F: 319/209 = 1.52) F (M/F: 434/657 = 0.66) N/A
Fentanyl as sole drug or in combination Fentanyl sole drug: 307/559 = 54.9%
cases.
N/A N/A
Concomitant drugs reported: other
opioids (69.0%), cocaine (9.5%),
benzodiazepines (6.8%), cannabis
(5.6%), and ethanol (5.2%)
National Institute on Drug Abuse [NIDA], 2017; Pichini et al.,
2018; Ventura et al., 2018). Although their chemistry is similar
to fentanyl, they are not routinely detected (O’Donnell et al.,
2018) and may present with a higher/much higher potency
than the parental compound. Most popular fentanyl derivatives
include: carfentanil (approximately 10,000 times more potent
than morphine), acetyl-fentanyl (about 15 times more potent
than morphine), and butyrfentanyl (30 times more potent than
morphine; Prekupec et al., 2017; Zawilska, 2017; Pichini et al.,
2018).
Aims
To assess fentanyl misuse/abuse/dependence and withdrawal-
related issues, we aimed here at analyzing the European
Medicines Agency [EMA] EudraVigilance (EV) database, and
comparing it with the United Kingdom Medicine and Healthcare
products Regulatory Agency (MHRA) Yellow Card scheme
(YCS), and the United States Food and Drug Administration
[FDA] Adverse Event Reporting System [FAERS] databases.
MATERIALS AND METHODS
EudraVigilance (EV) Features
European Medicines Agency (EMA) data were collected through
EV, i.e., the pharmacovigilance dataset which manages and
analyses information on suspected adverse reactions to medicines
which have been authorized in the European Economic Area
(EEA) (European Medicines Agency [EMA], 2007). This dataset
is a centralized database of all suspected adverse drug reactions
(ADRs) submitted to EMA through Individual Case Safety
Reports (ICSR), providing information related to an individual
case of a suspected side effect due to a medicine. Specifically,
an ADR is defined as “. . .a response which is noxious and
unintended, and which occurs at doses normally used in humans
. . .f An ADR, contrary to an adverse event, is characterized by the
suspicion of “. . .a causal relationship between the drug and the
occurrence. . .” (European Medicines Agency [EMA], 2017). The
ADRs here considered were, per se, spontaneous and unsolicited
communications reported by both Regulatory Authorities of
the EU Member States where the reaction occurred, and/or by
the Marketing Authorization Holders for those ADRs occurring
outside the EEA. Consistent with the EV Access Policy (European
Medicines Agency [EMA], 2016), data were made available here
after a formal, ad hoc, request regarding fentanyl, including the
following molecules: “fentanyl,” “fentanyl hydrochloride,” and
“fentanyl buccal,” with all pharmaceutical combinations having
been excluded. For each reported case, EV recorded Level 2A
information, meaning: general information on the ADR (e.g.,
code number of the ADR, sender type, sender organization,
type of report, date when the report was first received, primary
source country, reporter qualification, seriousness of the case,
and medical confirmation of the case), information on the
patient (age, sex, weight, and height), type of reaction/event,
drug information (e.g., type of drug, dosages, administration
route, and duration), including concomitant licit and illicit
drugs, medical history and comments, outcome of the reaction
including death, literature references (European Medicines
Agency [EMA], 2016, 2018). Each ADR was recorded according
to the Medical Dictionary for Regulatory Activities (MedDRA)
(Medical Dictionary for Regulatory Activities [MedDRA], 2017),
and listed through Preferred Terms (PT). PTs are defined as
“distinct descriptor (single medical concept) for a symptom, sign,
disease diagnosis, therapeutic indication, investigation, surgical
or medical procedure, and medical social or family history
characteristic” (Medical Dictionary for Regulatory Activities
[MedDRA], 2017).
In the data analysis of our study we included the ADR
identified by the following PT: “dependence,” “drug abuse,” “drug
abuser,” “drug dependence,” “drug diversion,” “drug withdrawal
syndrome,” “intentional product misuse,” “intentional product
use issue,” “intentional overdose,” “overdose,” “substance
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use,” “substance abuse,” and “withdrawal syndrome” (Medical
Dictionary for Regulatory Activities [MedDRA], 2017). The
following ADRs were excluded from the analysis: “accidental
exposure,” “accidental overdose,” “drug administration error,”
“drug prescribing error,” “toxicity to various agents,” “medication
error,” and “off-label use.” ADRs’ numbers differed from those
referring to single patients, since different reporters/senders
could have independently flagged the same ADR to EMA,
or several ADRs (involving various organ classes and so
identified with specific PT) related to the primary searched
ADRs (abuse/misuse/dependence and withdrawal ADRs) for
the same patient could have been reported as well. A descriptive
analysis of ADRs and cases (which were unequivocally identified
by an EV local number) was then performed, according to
the information provided (Medical Dictionary for Regulatory
Activities [MedDRA], 2017).
Access to the UK MHRA YCS and FAERS
Pharmacovigilance Datasets
In order to obtain a better understanding of prescribing fentanyl
misuse issues, publicly accessible, 2004–2018, data from both
the UK MHRA YCS (Medicines and Healthcare products
Regulatory Agency [MHRA], 2018b) and the FAERS (Food and
Drug Administration [FDA] Adverse Event Reporting System
[FAERS], 2018) were here analyzed as well. These data are made
available via online public dashboards.
The YCS collects information on a range of ADRs
spontaneously reported from healthcare professionals, members
of the public, and pharmaceutical companies, this information
are then entered onto the MHRA’s ADR database by a team
of safety experts to assess the likelihood of causal relationship
between the drug and the reported reactions. The YCS publishes
cumulative listings of all suspected ADRs received through
interactive Drug Analysis Profiles (iDAPs) (Medicines and
Healthcare products Regulatory Agency [MHRA], 2018a). After
selecting the iDAP related to “fentanyl,” a general overview of
data relating to: age, gender, and type of reactions (organized by
System Organ Class-SOC and MedDRA Preferred Terms – PTs)
was made available online. A range of filters to the database were
then applied here, with the time-frame and reactions selected
being those used for the EV dataset (Medical Dictionary for
Regulatory Activities [MedDRA], 2017).
The FAERS is a database that contains a range of voluntarily
submitted adverse event reports (Food and Drug Administration
[FDA] Adverse Event Reporting System [FAERS], 2018), with
these events being coded using terms from the MedDRA
dictionary (Medical Dictionary for Regulatory Activities
[MedDRA], 2017). Searching for “fentanyl,” “fentanyl
hydrochloride,” and “fentanyl buccal,” we gained access to a
range of FAERS-related data, which were then properly filtered
according to the type of reaction, consistent with the above
described EMA and YCS data extraction modalities.
Ethics Statement
Complying with the European Data Protection legislation
(e.g., Regulation (EC) No 45/2001EMA, European Medicines
Agency [EMA] (2016)), the protection of privacy and integrity
of individuals is guaranteed. Thus, all EMA data are fully
and completely de-identified/anonymized; therefore, any patient
identifier is not being disclosed. Similarly, both the YCS data and
FAERS data are completely anonymized and fully de-identified.
The study has been approved by the University of Hertfordshire
Ethics’ Committee (reference number LMS/PGR/UH/03234,
March 5, 2018).
RESULTS
The analysis of the two ADR-related datasets showed an overall
increase in the number of reports since 2004 to 2018, with two
peaks in the trend having been identified in the EV database,
respectively, in 2008 (885 ADRs) and 2015 (1,081 ADRs).
Conversely, YCS data remained broadly stable at relatively
low levels, being slightly increasing from 2014, with 101 cases
reported in 2017 (Figure 1).
Analysis of Data From the EV Database
During the period 2004–2018, the EMA EV system received a
total of 127,313 ADRs (referring to n = 6,161 patients/single
cases) relating to fentanyl misuse/abuse/dependence/withdrawal
issues (Table 1). Out of these 127,313 ADRs, some 14,287
(corresponding to 559 patients) were identified following a
further filtering exercise, whilst considering: (a) the PTs selected,
and (b) the “suspect” fentanyl role in causing the index ADR
case. The most represented ADRs were: “drug dependence”
(10,982/14,287 ADRs, 76.87% of the total), “intentional product
misuse” (1,866 ADRs, 13.06% of the total), and “drug abuse”
(1,065 ADRs, 7.45%). Most reports (17.2%) were related to ADRs
occurred in the United States and were posted by clinicians
(10.82%). Out of these 559 individual cases, 429 (76.74%)
were males (M/F: 319/209 = 1.52) in the 35–64 years-old
age range; conversely, 10 subjects were younger than 12, and
all had been diagnosed with an iatrogenic opioid withdrawal
syndrome. Significant levels of ADR cases required either a
prolonged hospitalization (192/559 = 34.35%) or resulted in
death (185/559 = 33.09%).
Among the 185 fatal cases, the most reported causes of death
were: toxicity to various agents (26/185 = 14.05%), drug abuse
(19/185 = 10.27%), and overdose (18/185 = 9.73%). Although
co-morbidity data went here typically unreported, chronic pain
conditions (n = 36) were the most frequently mentioned medical
conditions, whilst most typical psychiatric diagnoses included
mood (55 cases) and anxiety (33 cases) disorders.
Although in most cases fentanyl was identified on its
own (307/559 = 54.9% cases) concomitant drugs most
typically mentioned in the EMA database included:
remaining opiates/opioids (174/252 = 69%), cocaine
(24/252 = 9.5%), benzodiazepines (17/252 = 6.8%), and cannabis
(14/252 = 5.6%). Even though fentanyl’s route of administration
was infrequently reported (e.g., oral: 41/559 = 7.3%, and
transdermal: 33/559 = 5.9%), a range of idiosyncratic ways
of administration/high dosage intake were here described,
e.g.: 23 cases of transdermal patches’ ingestion, 10 cases of
fentanyl nasal administration/inhalation, and 10 cases of
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FIGURE 1 | 2004–2018 EMA and MHRA misuse/abuse/dependence/withdrawal-related fentanyl cases. EMA, European Medicines Agency; MHRA, Medicines and
Healthcare products Regulatory Agency.
intravenous/parenteral use, with a case of tampered transdermal
patches’ injection on some 30 times a day having been reported.
In terms of idiosyncratic dosages, a patient was here reported
to be self-administering with 800 mcg 2–3 times/day, whilst
another was daily self-administering with 11.56 mg of fentanyl
transdermal patch. Where available, most typically reported
blood toxicology screening results were in the range of: up to
10 ng/ml (7/559 cases), 10–50 ng/ml (16/559 cases), and in excess
of 100 ng/ml (2/559 cases, in 1 case this was 313 ng/ml).
Analysis of the YCS and FAERS
Databases
Analysis of the 2004–2018 fentanyl YCS iDAPs identified some
3,566 fentanyl misuse/abuse/dependence/withdrawal-related
ADRs, corresponding to 1,165 single patients/cases (Table 1).
ADR numbers showed an increase over time (Figure 1), with
a peak in 2017 (101 reactions). Female subjects (F/M: 657/434
reports), aged 40–59 years (308 reports), were most typically
involved. Out of all reactions, “withdrawal” (79 reactions),
“intentional product misuse and use issues” (62 reactions),
“overdoses” (56 reactions), and “addiction/dependence/drug
dependence” (45 reactions) were the most typically represented
ADRs (Table 1). Moreover, in the 2004–2018-time frame, the
FAERS database identified a total (e.g., all causes ADRs) of
78,885 instances. After completion of the above-described
filtering exercise, a total of 19,145 misuse/abuse/dependence
cases/patients were here identified. Most frequently mentioned
reports related to: “overdose” (n = 8,255/19,145, 43.11%),
“withdrawal syndrome” (n = 3,983, 20.80%), “drug use
disorder/drug abuse/drug diversion” (n = 3,886, 20.29%),
“intentional product use issues/misuse” (n = 1,829, 9.55%), and
“drug dependence” (n = 1,462, 7.64%) (Table 1).
DISCUSSION
This unprecedented, large scale, research study aimed at
systematically identifying and analyzing a total of some 26,500
fentanyl misuse/abuse/dependence/withdrawal cases. Present
data were extracted from a range of high-quality (Schifano
and Chiappini, 2018) pharmacovigilance databases, such
as the EV (providing description on a total of unfiltered
6,161 misuse/abuse/dependence/withdrawal cases), the
United Kingdom YCS (1,165 cases), and the United States
FAERS (19,145 cases). Indeed, these data seem to once again
confirm that non-medical prescription high potency opioid use
is a major public health concern both in Europe (European
Monitoring Centre for Drug and Drug Addiction [EMCDDA],
2015), and in the United States (Ali et al., 2017; Mital et al.,
2018). According to European Monitoring Centre for Drug and
Drug Addiction [EMCDDA] (2015) data, the main consumers
in the EU in 2008 per million inhabitants per day were Belgium
(13,601 Defined Daily Doses or S-DDD), Germany (13,341
S-DDD), and Austria (10,143 S-DDD). Moreover, even though
illegally diverted fentanyl is a relatively marginal phenomenon
in most EU countries, in Estonia as many as 70% of applicants
for treatment services in 2009 reported fentanyl as their primary
drug. Consistent with this, Han et al. (2017) in carrying out
the 2015 National Survey on Drug Use and Health (NSDUH)
exercise, analyzed data from 51,200 subjects who completed
an ad hoc survey interview. They estimated that out of 91.8
million (37.8%) United States non-institutionalized adults
who used prescription opioids, 11.5 million misused them,
and 1.9 million had a use disorder. Being relief of physical
pain the most commonly reported motivation for misusing
prescription opioids (Han et al., 2017), developing new pain
treatments would possibly reduce the access to opioids in
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high-risk patients (National Institute on Drug Abuse [NIDA],
2017). A further challenge may be constituted by identifying new
opioid formulations with physical or pharmacologic deterrents
to reduce tampering (Stanos et al., 2012; Passik, 2014).
After many years of stability, fentanyl ADRs seemed to have
peaked here over the last 10 years and in the United States even
more dramatically just over the last 2 years or so. Although
it is possible that high levels of reporting were facilitated by
a recently growing awareness on fentanyl misuse, and may
somehow mirror as well the increasing rates of worldwide
availability of this medication (United Nations Office on Drugs
and Crime [UNODC], 2017), present figures are in line with
previous findings (Ali et al., 2017). However, increasing rates of
fentanyl misuse/abuse issues may have been facilitated as well by
the high number of pro drug websites/users’ fora, where proper
advice on how to both tamper fentanyl patches and best enjoy the
related intake experience as well are given (Drugs-forum, 2017;
The hive, 2018).
Possibly because of its high potency (Frisoni et al., 2018),
fentanyl prescribing was here reported in a number of cases
to be associated with iatrogenic dependence/withdrawal issues.
It is a further reason of concern, however, that fentanyl
was here self-administered either in idiosyncratic ways (i.e.,
parenteral, ingesting the transdermal patches) or at high/very
high dosages to achieve significant blood levels (Frisoni et al.,
2018). A large proportion of EMA ADR cases (e.g., roughly
two out of three) was here associated either with a prolonged
hospitalization or resulted in death. Fatalities related to novel
synthetic opioids and fentanyls should be investigated using
a multidisciplinary approach, aiming at framing each case
and directing the investigations toward targeted toxicological
analyses. This approach should be adopted routinely (Hikin
et al., 2018), and especially in cases of death from uncertain
or questionable causes (Lucyk and Nelson, 2017; Prekupec
et al., 2017; Drummer, 2018). New approaches for the detection
of potential unknown psychoactive substances, e.g., in the
Emergency Departments, need to be developed, in order to
identify and classify compounds that are new to the market
and absent from existing chemical libraries (Assi et al., 2015;
Guirguis et al., 2017; Calvo-Castro et al., 2018; Food and Drug
Administration [FDA], 2018; News Release, 2018).
Although in some 54.9% of EMA ADRs a fentanyl intake was
reported on its own, a range of both prescribing (e.g., remaining
opiates/opioids, benzodiazepines), and recreational (e.g., cocaine
and cannabis) psychotropics was here identified as well. Whilst
these combinations are likely to lead to intoxication or death
(Haukka et al., 2018), they may reflect the characteristics of clients
prescribed with fentanyl, e.g., frequently affected by chronic pain
conditions, anxiety, and depression, at times presenting as well
with a history of drug misuse (Hughes et al., 2016).
Intake of high fentanyl dosages was possibly associated here
with the need to relieve pain, whilst attempting to cope with
the molecule’s increasing levels of tolerance overtime (Han et al.,
2017). Nonetheless, fentanyl recreational value (Frisoni et al.,
2018) should not be overlooked (Drummer, 2018). High fentanyl
dosages may be associated with respiratory arrest, pulmonary
oedema, chest wall rigidity and apnoea. A reported uncommon
intoxication symptom is chest pain, with non-specific T-wave
changes on the electrocardiogram, mimicking an acute coronary
syndrome (for a thorough review, see Frisoni et al., 2018).
LIMITATIONS
Even though the study of spontaneous reporting systems, such as
EV, the YCS, and the FAERS, should be considered as a starting
point for mapping the new trends of abuse, including the abuse
of prescription drugs, the analysis of voluntarily reported ADRs
may have some limitations. These pharmacovigilance database
approach limitations include likely underreporting, reporting
bias, and lack of access to the full range of available data.
Some ADRs may be signaled several times by different reporters,
therefore the number of suspected ADRs can be different to
the number of cases as one individual case may refer to several
suspected ADRs. Moreover, a report may describe different
information, sometimes lacking useful data, such as medical
history, dosages and route of administration, or cause of death
when the outcome is fatal. Case reports of suspected ADRs do
not confirm that a certain effect in a patient has been caused
by a specific medicine (European Medicines Agency [EMA],
2011; Food and Drug Administration [FDA] Adverse Event
Reporting System [FAERS], 2018; Medicines and Healthcare
products Regulatory Agency [MHRA], 2018b), but may be
used for detecting and assessing eventual safety issues to be
investigated. Again, the worldwide fentanyl prescribing rates
were not available here and, due to fentanyl’s availability on the
black and gray (semi-legal) markets, the true incidence of the
misusing phenomenon may not be calculated.
Finally, because of only partial consistency of data collection of
the datasets here examined, analyzing and comparing figures may
prove problematic. Indeed, MHRA and FAERS public dashboards
provided here only a portion of available data (e.g., excluding
diagnoses, medical histories, fentanyl dosages and concomitant
drugs ingested) relating to the cases reported.
CONCLUSION
Fentanyl abuse may be considered a public health issue, with
enormous implications for the clinical practice. A national
registry of patients to monitor and check opioid prescribing to
high-risk patients would be helpful, this may improve the patient
safety levels, whilst providing more focused epidemiological data
regarding prescribing patterns (Mordecai et al., 2018). With the
aim of reducing the number of people addicted to opioids, the
FDA strategy is now to pose a control on prescription duration
and doses for patients (Floyd and Warren, 2018; Food and Drug
Administration [FDA], 2018).
In terms of prevention of the opiate epidemic and
harm reduction strategies, it is here suggested that users
should play an active role in helping drafting overdose
education and abuse-deterrent strategies. Prompt referral/self-
referral to treatment programs has been reported as being
an effective intervention (Suzuki and El-Haddad, 2017;
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Ralphs and Gray, 2018; Schiller and Mechanic, 2018;
Younga et al., 2018). In Europe, a range of evidence-
based prevention programs have been implemented over
the last few years (European Monitoring Centre for Drug
and Drug Addiction [EMCDDA], 2017). Supervised drug
consumption facilities and “take-home“ naloxone programs,
making the medication available to opioid users and their
partners/peers/families, alongside with training in overdose
recognition and response, appear to be helpful in preventing
deaths (European Monitoring Centre for Drug and Drug
Addiction [EMCDDA], 2018a) and should be encouraged
(Uusküla et al., 2015). Moreover, the Welsh Emerging
Drugs and Identification of Novel Substances [WEDINOS],
2018, the Loop in the United Kingdom (Wearetheloop.org,
2018), the Drug Information and Monitoring System in the
Netherlands (Drug Information and Monitoring System [DIMS],
2018 and the MANchester DRug Analysis and Knowledge
Exchange [MANDRAKE], 2018) are some drug awareness/harm
reduction European projects aiming at monitoring the illegal
drug market, identifying public health threats at an early
stage.
Physicians should be educated and invited to a responsible
prescribing of drugs with a diversion potential, whilst carefully
evaluating the possibility for some clients (e.g., people with a
personal history of drug abuse) to be more vulnerable to drug
misuse (Han et al., 2017).
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